Search Within

Maurizio Scaltriti

Formats
  1. Journal Article (94)
  2. Meeting Abstract (68)
  3. Book Section (3)
  4. Review (3)
  5. Guidelines (1)
  6. Research Letter (1)
Groups
  1. GSK Faculty (89)
  2. Sloan Kettering Institute Postdocs (86)
  3. Department of Medicine (80)
  4. Solid Tumor Oncology Division (79)
  5. Human Oncology and Pathogenesis Program (60)
  6. Center for Molecular Imaging and Biotechnology (CMIB) (55)

More Groups

People
  1. Jose Baselga (63)
  2. Pedram Razavi (32)
  3. David Hyman (27)
  4. Michael Berger (27)
  5. Sarat Chandarlapaty (26)
  6. Emiliano Cocco (25)

More People

Years
  1. 2025 (1)
  2. 2023 (2)
  3. 2022 (6)
  4. 2021 (16)
  5. 2020 (27)
  6. 2019 (26)

More Years

Publications
  1. Cancer Research (37)
  2. Annals of Oncology (16)
  3. Clinical Cancer Research (12)
  4. Cancer Discovery (8)
  5. Journal of Clinical Oncology (8)
  6. Cancer Cell (6)

More Publications

Publishers
  1. American Association for Cancer Research (59)
  2. Nature Publishing Group (20)
  3. Oxford University Press (17)
  4. Elsevier Inc. (12)
  5. American Association for the Advancement of Science (10)
  6. American Society of Clinical Oncology (9)

More Publishers

Results (170)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • ARID1A is a critical regulator of luminal identity and therapeutic response in estrogen receptor-positive breast cancer
    Meeting Abstract

    Toska, E.; Xu, G.; Chhangawala, S.; Cocco, E.; Razavi, P.; Otto, J.; Cai, Y.; Chan, C.; D'Avino, D. R.; Collings, C.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Genomic profiling of metastatic breast cancer identifies the Hippo pathway to be a key determinant of CDK4/6 inhibitor sensitivity
    Meeting Abstract

    Razavi, P.; Li, Q.; Li, Z.; Brown, D. N.; Ping, C.; Shen, R.; Sanchez-Vega, F.; Schultz, N. D.; Baselga, J.; Scaltriti, M.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Resistance to TRK inhibition mediated by convergent MAP kinase pathway activation
    Meeting Abstract

    Cocco, E.; Kulick, A.; Misale, S.; Yaeger, R.; Razavi, P.; Won, H. H.; Ptashkin, R.; Hechtman, J. F.; Toska, E.; Cownie, J.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Double PIK3CA mutations in cis enhance oncogene activation and sensitivity to PI3K alpha inhibitors in breast cancer
    Meeting Abstract

    Vasan, N.; Razavi, P.; Johnson, J.; Shao, H.; Shah, H.; Antoine, A.; Ladewig, E.; Gorelick, A.; Toska, E.; Xu, G.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • PI3K pathway mediated splicing defects in ER+ breast cancers
    Meeting Abstract

    Ladewig, E.; Fairchild, L.; Scaltriti, M.; Leslie, C.; Toska, E.; Baselga, J.
    Cancer Research (2019)

    Fulltext@MSK | Save
  • CDK6 overexpression promotes resistance to CDK4/6 inhibitors in breast cancer
    Meeting Abstract

    Li, Q.; Razavi, P.; Li, Z.; Da Cruz Paula, A. F.; Brogi, E.; Scaltriti, M.; Reis, J. S.; Chandarlapaty, S.
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Resistance to TRK inhibition mediated by convergent MAPK pathway activation
    Research Letter

    Cocco, E.; Schram, A. M.; Kulick, A.; Misale, S.; Won, H. H.; Yaeger, R.; Razavi, P.; Ptashkin, R.; Hechtman, J. F.; Toska, E.; more...
    Nature Medicine (2019)

    Fulltext@MSK | Save
  • ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research
    Guidelines

    Marchiò, C.; Scaltriti, M.; Ladanyi, M.; Iafrate, A. J.; Bibeau, F.; Dietel, M.; Hechtman, J. F.; Troiani, T.; López-Rios, F.; Douillard, J. Y.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Primary and secondary results of the first nationwide molecular screening program in Spain for patients with advanced breast cancer (AGATA SOLTI-1301 study)
    Meeting Abstract

    Pernas, S.; Villagrasa, P.; Nuciforo, P. G.; Vivancos, A.; Scaltriti, M.; Rodon, J.; Burgues, O.; Canes, J.; Duenas, M.; Cecchi, F.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Double PIK3CA mutations in cis enhance PI3Kα oncogene activation and sensitivity to PI3Kα inhibitors in breast cancer
    Meeting Abstract

    Vasan, N.; Razavi, P.; Johnson, J. L.; Shao, H.; Reznik, E.; Smith, M. L.; Sebra, R.; Cantley, L. C.; Scaltriti, M.; Baselga, J.
    Annals of Oncology (2019)

    Fulltext@MSK | Save